Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Buy
67
EKG Quote, Financials, Valuation and Earnings
Last price:
$15.96
Seasonality move
:
2.92%
Day range:
$16.27 - $16.27
52-week range:
$15.23 - $18.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
20
Avg. volume:
1.1K
1-year change:
-2.19%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
$16.27 | -- | -- | -- | $0.00 | 0% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$19.55 | -- | -- | -- | $0.24 | 1.23% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$10.66 | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | 1.696 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.069 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.328 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EKG
First Trust Nasdaq Lux Digi Health Solutions ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
First Trust Nasdaq Lux Digi Health Solutions ETF vs. Competitors
-
Which has Higher Returns EKG or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to First Trust Nasdaq Lux Digi Health Solutions ETF's net margin of --. First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About EKG or BBC?
First Trust Nasdaq Lux Digi Health Solutions ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust Nasdaq Lux Digi Health Solutions ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe First Trust Nasdaq Lux Digi Health Solutions ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is EKG or BBC More Risky?
First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.080, suggesting its more volatile than the S&P 500 by 7.979%.
-
Which is a Better Dividend Stock EKG or BBC?
First Trust Nasdaq Lux Digi Health Solutions ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 1.23% to investors and pays a quarterly dividend of $0.24 per share. First Trust Nasdaq Lux Digi Health Solutions ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EKG or BBC?
First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. First Trust Nasdaq Lux Digi Health Solutions ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, First Trust Nasdaq Lux Digi Health Solutions ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust Nasdaq Lux Digi Health Solutions ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns EKG or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to First Trust Nasdaq Lux Digi Health Solutions ETF's net margin of --. First Trust Nasdaq Lux Digi Health Solutions ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About EKG or CNCR?
First Trust Nasdaq Lux Digi Health Solutions ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that First Trust Nasdaq Lux Digi Health Solutions ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe First Trust Nasdaq Lux Digi Health Solutions ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is EKG or CNCR More Risky?
First Trust Nasdaq Lux Digi Health Solutions ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.282%.
-
Which is a Better Dividend Stock EKG or CNCR?
First Trust Nasdaq Lux Digi Health Solutions ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. First Trust Nasdaq Lux Digi Health Solutions ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EKG or CNCR?
First Trust Nasdaq Lux Digi Health Solutions ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. First Trust Nasdaq Lux Digi Health Solutions ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, First Trust Nasdaq Lux Digi Health Solutions ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for First Trust Nasdaq Lux Digi Health Solutions ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EKGFirst Trust Nasdaq Lux Digi Health Solutions ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
